Abstract
Background: Subarachnoid hemorrhage (SAH) is considered as a violent disease with high rate of morbidity and mortality. Early brain injury (EBI) and delayed vasospasm are the two aspects of this disease that are becoming research hotspots.
Objective: We aim to update the role of oxidative stress in the development of EBI and delayed cerebral vasospasm after SAH. Method: We reviewed early researches, and mainly discussed three aspects of contents: reactive oxygen species (ROS) production, the role of oxidative stress in early brain injury and delayed vasospasm, and clinical implications. Results: There are several sources for the excessive generation of oxidants after SAH such as disrupted mitochondrial respiration, upregulated enzymatic pathways, extracellular hemoglobin degradation and depressed intrinsic antioxidant systems. Neuron apoptosis induced by ROS is one vital mechanism of EBI. And extracellular hemoglobin degradation and nitric oxide synthases up-reputation are involved in the pathogenesis of delayed cerebral vasospasm. Some antioxidants show significant neuroprotection in researches. Conclusion: ROS production increases in SAH via mitochondria, hemoglobin or enzymatic pathway, and it plays a vital important role in SAH. It seems that antioxidant therapy will be most effective as one component in a treatment regime that attempts to address all the different pathways to EBI and vasospasm following SAH.Keywords: Delayed vasospasm, early brain injury, oxidatives stress, subarachnoid hemorrhage.
Current Drug Delivery
Title:The Updated Role of Oxidative Stress in Subarachnoid Hemorrhage
Volume: 14 Issue: 6
Author(s): Yang Yang, Sheng Chen*Jian-Min Zhang
Affiliation:
- Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, 310009, Hangzhou, Zhejiang,China
Keywords: Delayed vasospasm, early brain injury, oxidatives stress, subarachnoid hemorrhage.
Abstract: Background: Subarachnoid hemorrhage (SAH) is considered as a violent disease with high rate of morbidity and mortality. Early brain injury (EBI) and delayed vasospasm are the two aspects of this disease that are becoming research hotspots.
Objective: We aim to update the role of oxidative stress in the development of EBI and delayed cerebral vasospasm after SAH. Method: We reviewed early researches, and mainly discussed three aspects of contents: reactive oxygen species (ROS) production, the role of oxidative stress in early brain injury and delayed vasospasm, and clinical implications. Results: There are several sources for the excessive generation of oxidants after SAH such as disrupted mitochondrial respiration, upregulated enzymatic pathways, extracellular hemoglobin degradation and depressed intrinsic antioxidant systems. Neuron apoptosis induced by ROS is one vital mechanism of EBI. And extracellular hemoglobin degradation and nitric oxide synthases up-reputation are involved in the pathogenesis of delayed cerebral vasospasm. Some antioxidants show significant neuroprotection in researches. Conclusion: ROS production increases in SAH via mitochondria, hemoglobin or enzymatic pathway, and it plays a vital important role in SAH. It seems that antioxidant therapy will be most effective as one component in a treatment regime that attempts to address all the different pathways to EBI and vasospasm following SAH.Export Options
About this article
Cite this article as:
Yang Yang, Chen Sheng*, Zhang Jian-Min, The Updated Role of Oxidative Stress in Subarachnoid Hemorrhage, Current Drug Delivery 2017; 14 (6) . https://dx.doi.org/10.2174/1567201813666161025115531
DOI https://dx.doi.org/10.2174/1567201813666161025115531 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tissue Elastography: Advances in Imaging the Mechanical Properties of Tissue
Recent Patents on Electrical Engineering Palmitoylethanolamide Restores Myelinated-Fibre Function in Patients with Chemotherapy-Induced Painful Neuropathy
CNS & Neurological Disorders - Drug Targets Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage
Current Pharmaceutical Design Recent Patents, Regulatory Issues, and Toxicity of Nanoparticles in Neuronal Disorders
Current Drug Metabolism NMR in Metabolic Profiles of Neural Stem/Progenitor Cells: Current Status and Relevant Problems
Current Medical Imaging Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Role of Adenosine in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Disease-Related Changes in TRPV1 Expression and Its Implications for Drug Development
Current Topics in Medicinal Chemistry Differential Regulation of microRNAs in Patients with Ischemic Stroke
Current Neurovascular Research Traumatic Brain Injury: Preclinical Imaging Diagnostic(s) and Therapeutic Approaches
Current Pharmaceutical Design Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain
Current Medicinal Chemistry Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Regenerative Medicine Organotypic Cultures as Tool to Test Long-Term Effects of Chemicals on the Nervous System
Current Medicinal Chemistry Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Dental Pulp from Human Exfoliated Deciduous Teeth-derived Stromal Cells Demonstrated Neuronal Potential: In Vivo and In Vitro Studies
Current Stem Cell Research & Therapy Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors
Current Drug Delivery Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery